Jeremy Goldberg

Senior Advisor
Contact Us

 

Jeremy Goldberg has over 25 years of experience, mainly focused on investing and business development in the pharmaceutical and healthcare industries. Jeremy has been an operating executive in a $1B + sales pharmaceutical company, a partner in a venture capital fund, and an entrepreneurial founder of several companies that were later acquired, and has advised leading financial firms that advise or invest in healthcare companies, including a leading $5B private equity fund Arsenal Capital Partners, Torreya Partners, and TPG Sixth Street Partners (the $30B credit fund within $100B TPG funds.)

Jeremy served as Managing Director, Corporate Development for Endo Pharmaceuticals (Nasdaq: ENDP), a leading pain therapeutics company, from 2003-2008. In this position, Jeremy was responsible for Endo’s overall corporate development activities, including structuring, negotiating and closing transactions such as the acquisitions of companies, products and product lines. Prior to Endo, Jeremy was a founding partner of ProQuest Investments from 1997-2002, the first cancer-focused venture capital fund, where he and partners raised over $250M in Funds I, II to acquire positions in biotechnology, specialty pharmaceutical, and medical device companies. Representative investments or deals sourced include Conforma Therapeutics (acquired by Biogen IDEC), Threshold Pharmaceuticals, and Pharmion (acquired by Celgene).

Prior operating experience includes roles as founding CEO or founder of three biotechnology companies that were acquired or taken public, including Versicor (Vicuron), a Sepracor spin-out later acquired by Pfizer for $1.9B, as well as operating positions at SmithKline (now Glaxo SmithKline) and Becton Dickinson. Jeremy is a magna cum laude graduate of Harvard College in biochemistry and East Asian History, and Harvard Business School with distinction (top 10% of class).

Jeremy has served on the Visiting Committees at Dana Farber Cancer Institute since 1999 and on the board of the International Research Alliance, a private sector philanthropy supporting NIH and Oxford and Cambridge University since 2007. He serves on the boards of Harvard Business School Healthcare Alumni organization and Einstein Health Network in Philadelphia.